Compare Twist Bioscience Corp (TWST) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Yum China Holdings Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.26B), while Yum China Holdings Inc trades at $42.55 (market cap $14.48B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.72% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | YUMC | |
|---|---|---|
Market Cap | $8.26B | $14.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $153.10 | $57.95 |
52-Week Low | $24.16 | $40.18 |
Enterprise Value | $8.18B | $15.39B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
YUMC trades at $43.34, down 0.6% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $0.70 surpassing the $0.67 estimate. Revenue grew to $11.80 billion in 2025, and net income reached $929 million. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of the Pizza Hut Burger Bar to 300 locations.
The outlook remains positive given strong analyst support, with 14 buy ratings and a consensus pointing to 25.6% upside. Key risks include execution of expansion plans and macroeconomic pressures in China. The stock presents a value opportunity with a P/E of 15.88 and solid profitability metrics, but investors should monitor competitive dynamics and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
